Announcements Trials
Browse Landscape

Status

Completed 582Unknown 160Terminated 144Recruiting 138Active not recruiting 94Withdrawn 57Not yet recruiting 40Suspended 4Enrolling by invitation 2Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Wounds and Injuries 1Carcinoma, Hepatocellular 1

Interventions

Afatinib 33-Iodobenzylguanidine 3niraparib 2lenvatinib 2ibrutinib 2gallium 68 PSMA-11 2abemaciclib 2Trastuzumab 2Sunitinib 2Ramucirumab 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Gefitinib 2Fluorouracil 2Capecitabine 2Amifampridine 2Abiraterone Acetate 2zenocutuzumab 1vorasidenib 1tucatinib 1trilaciclib 1trifluridine tipiracil drug combination 1tovorafenib 1talquetamab 1tafasitamab 1selpercatinib 1sacituzumab govitecan 1ripretinib 1pralsetinib 1ponatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Approved for marketing × Leucovorin × Clear all
NCT02436044 2019-08-20

HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC

Sun Yat-sen University

Approved for marketing
Gastrointestinal

Carcinoma, Hepatocellular, Wounds and Injuries

Data powered by HemOnc (CC BY 4.0) Colophon âš¡